Company Description
Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally.
The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform.
Its OA pain management products include Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide short-and long-term pain relief.
The company’s joint preservation and restoration product family comprises orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants to treat upper and lower extremity orthopedic conditions.
In addition, the company offers non-orthopedic products comprising HA-based products for Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier for use after abdominal-pelvic surgeries; and Hyalomatrix for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic.
Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.
| Country | United States |
| Founded | 1983 |
| IPO Date | Apr 29, 1993 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 288 |
| CEO | Cheryl Blanchard |
Contact Details
Address: 32 Wiggins Avenue Bedford, Massachusetts 01730 United States | |
| Phone | 781 457 9000 |
| Website | anika.com |
Stock Details
| Ticker Symbol | ANIK |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000898437 |
| CUSIP Number | 035255108 |
| ISIN Number | US0352551081 |
| Employer ID | 04-3145961 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Dr. Cheryl Renee Blanchard Ph.D. | President, Chief Executive Officer and Director |
| Stephen D. Griffin | Executive Vice President, Chief Financial Officer and Chief Operating Officer |
| David Colleran J.D. | Executive Vice President, General Counsel and Corporate Secretary |
| Ian W. McLeod | Vice President and Chief Accounting Officer |
| Mark Namaroff | Vice President of Investor Relations, ESG and Corporate Communications |
| James Chase | Senior Vice President of International Sales and Marketing |
| Ben Joseph | Vice President of Commercial and Corporate Development |
| Lisa Funiciello | Vice President of Human Resources |
| Mira Leiwant | Senior Vice President of Regulatory, Quality and Clinical Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 30, 2025 | 10-Q | Quarterly Report |
| Jul 30, 2025 | 8-K | Current Report |
| Jul 30, 2025 | 8-K | Current Report |
| Jun 24, 2025 | 8-K | Current Report |
| May 9, 2025 | 10-Q | Quarterly Report |
| May 9, 2025 | 8-K | Current Report |
| Apr 28, 2025 | ARS | Filing |
| Apr 28, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 28, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 17, 2025 | SCHEDULE 13G/A | Filing |